Market viability of ImmBioVax vaccines against H. Pylori and C. Difficile

Vaccines are not yet available to protect against H. Pylori and C. Difficile and the existing
therapeutic options available have significant limitations and challenges. Although quoted as
significant, the market size for vaccines against these pathogens are poorly defined and the
characteristics of a successful prophylactic vaccine product (e.g. production costs, duration of
action) are not well established. ImmunoBiology Ltd (ImmBio) intends to establish the
market size, intellectual property position and medical need for two potential new vaccines
against these pathogens as a necessary first step to establishing full vaccine development
projects.
Vaccine development activities are both long and costly, therefore it is essential to establish
proof of market including commercial viability before significant experimental work is
initiated. A full exploitation plan will be established as a part of this project defining the work
and costs that will be necessary to bring an effective vaccine to market. Activities will be
based on an existing vaccine technology platform "ImmBioVax" owned by ImmunoBiology
and proven to deliver vaccines possessing broad efficacy against pathogens such as N.
Meningitidis and Mtb.